The [ combination immunotherapy consisting ] of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with unresectable malignant pleural mesothelioma (MPM), confirms a 3-year updated analysis of the CheckMate 743 trial. After 3 years, 23% of patients who received combination … [Read more...]
Nivolumab/Ipilimumab Demonstrates Durable OS Benefit in Malignant Pleural Mesothelioma
[ An Opdivo plus Yervoy combination ] significantly improved overall survival (OS) versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma, according to findings from a prespecified analysis of the phase 3 CheckMate-743 trial (NCT02899299) that were presented during the 2020 International … [Read more...]
Bristol-Myers Squibb’s Opdivo, Yervoy put the brakes on mesothelioma in phase 2
New phase 2 data suggest immunotherapy could stall mesothelioma progression—and that when it comes to Bristol-Myers Squibb’s checkpoint inhibitors, two might be better than one. Early results unveiled Monday at the American Society of Clinical Oncology annual meeting showed that Bristol’s PD-1 med Opdivo and CTLA4 drug Yervoy slowed disease growth … [Read more...]